VKTX
Q4 2026 EPS Estimate
$-1.07
Oct 28, 2026 · Reports after close
FY2030E EPS$2.28

Analyst Sentiment

Wall St. Consensus
Buy
24 analysts·High coverage
75
Score
23 Buy (96%)1 Hold (4%)0 Sell (0%)
Rating Breakdown
Strong Buy
14%
Buy
2292%
Hold
14%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$83.00
+152.0%
Consensus
$95.00
+188.4%
Bull
$101.00
+206.6%
12-Month Target Range24 analysts
$83.00$95.00$101.00
Current $32.94Consensus
Current Price
$32.94
Upside to Consensus
$62.06

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+2.53%
EPS
FY2028
Rev+2097.95%
EPS
FY2029
Rev+193.70%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$7M$7M$162M$474M$1.21B
Low$7M$7M$159M$474M$1.21B
High$7M$7M$164M$474M$1.21B
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-542M$-560M$-478M$-161M$257M
Low$-616M$-732M$-763M$-161M$257M
High$-438M$-270M$-64M$-161M$257M
EPS Avg$-4.60$-4.42$-3.66$-1.43$2.28
Low$-5.47$-6.50$-6.78$-1.43$2.28
High$-3.89$-2.40$-0.57$-1.43$2.28
Analysts (Rev / EPS)10 / 1411 / 1514 / 158 / 912 / 6
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-124M$-126M$-117M$-105M$-99M$-95M$-85M$-98M
Low$-167M$-180M$-117M$-105M$-99M$-95M$-85M$-98M
High$-80M$-82M$-117M$-105M$-99M$-95M$-85M$-98M
EPS Avg$-1.07$-1.08$-1.01$-0.90$-0.85$-0.82$-0.73$-0.84
Low$-1.44$-1.56$-1.01$-0.90$-0.85$-0.82$-0.73$-0.84
High$-0.69$-0.70$-1.01$-0.90$-0.85$-0.82$-0.73$-0.84
Analysts (Rev / EPS) / 12 / 12 / 5 / 5 / 5 / 5 / 6 / 6

Earnings Surprises

Recent Analyst Actions

May 28, 2026Lake Street
Viking Therapeutics initiated with a Buy at Lake Street
Target:$89.00
+181.1%from $31.66
May 27, 2026Truist Financial
Truist Securities Assumes Viking Therapeutic (VKTX) at Buy
Target:$83.00
+169.5%from $30.80
Apr 30, 2026Morgan Stanley
Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
Target:$95.00
+212.7%from $30.39
Apr 30, 2026Cantor Fitzgerald
Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald
Target:$100.00
+219.2%from $31.33
Mar 12, 2026Jefferies
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year"
Target:$101.00
+184.7%from $35.47
Feb 12, 2026Morgan Stanley
Viking Therapeutics price target lowered to $99 from $102 at Morgan Stanley
Target:$99.00
+218.6%from $31.07
Nov 12, 2025Canaccord Genuity
Viking Therapeutic (VKTX) PT Raised to $107 at Canaccord Genuity
Target:$107.00
+163.5%from $40.60
Oct 29, 2025Canaccord Genuity
Canaccord starts Viking Therapeutics with Buy on obesity potential
Target:$106.00
+203.5%from $34.93
Oct 23, 2025Morgan Stanley
Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley
Target:$102.00
+224.6%from $31.42
Oct 23, 2025Cantor Fitzgerald
Viking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald
Target:$105.00
+234.2%from $31.42
Apr 28, 2025Truist Financial
Viking Therapeutics price target lowered to $75 from $95 at Truist
Target:$75.00
+189.1%from $25.94
Dec 2, 2024Piper Sandler
Piper Sandler Starts Viking Therapeutic (VKTX) at Overweight
Target:$74.00
+39.8%from $52.94
Nov 4, 2024Laidlaw
Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)
Target:$110.00
+74.2%from $63.14
Nov 4, 2024Jefferies
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX)
Target:$110.00
+74.2%from $63.14
Jun 27, 2024Morgan Stanley
Viking Therapeutics initiated with an Overweight at Morgan Stanley
Target:$105.00
+121.6%from $47.39
Jun 25, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
Target:$90.00
+72.7%from $52.12
May 16, 2024Raymond James
Raymond James Upgrades Viking Therapeutic (VKTX) to Strong Buy
Target:$116.00
+68.0%from $69.06
May 16, 2024Truist Financial
Roche data falls short of Viking weight loss drug, says Truist
Target:$120.00
+72.6%from $69.53
Mar 26, 2024Oppenheimer
Viking Therapeutic (VKTX) PT Raised to $138 at Oppenheimer
Target:$138.00
+70.7%from $80.83
Mar 26, 2024BTIG
Viking Therapeutic (VKTX) PT Raised to $125 at BTIG
Target:$125.00
+48.8%from $83.98
Mar 26, 2024Stifel Nicolaus
Viking Therapeutic (VKTX) PT Raised to $95 at Stifel
Target:$95.00
+13.3%from $83.87
Mar 15, 2024BTIG
Viking Therapeutic (VKTX) PT Raised to $100 at BTIG
Target:$100.00
+59.8%from $62.56
Dec 24, 2022Maxim Group
Viking Therapeutics (VKTX) Stock Gets A $15 Price Target
Target:$15.00
+77.5%from $8.45
Dec 19, 2022BTIG
Madrigal's data bodes well for Viking's de-risked VK2809, says BTIG
Target:$20.00
+197.6%from $6.72
Dec 19, 2022H.C. Wainwright
Madrigal data 'great readthrough' for Viking, says H.C. Wainwright
Target:$21.00
+229.9%from $6.37
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.